Antifungal prophylaxis in chemotherapy-associated neutropenia: a retrospective, observational study
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2334
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Antifungal prophylaxis in chemotherapy-associated neutropenia: a retrospective, observational study ; volume:7 ; number:1 ; day:02 ; month:7 ; year:2007 ; pages:1-7 ; date:12.2007
BMC infectious diseases ; 7, Heft 1 (02.7.2007), 1-7, 12.2007
- Urheber
-
Riedel, Amy
- Beteiligte Personen und Organisationen
-
Choe, Lan
Inciardi, John
Yuen, Courtney
Martin, Thomas
Guglielmo, B Joseph
SpringerLink (Online service)
- DOI
-
10.1186/1471-2334-7-70
- URN
-
urn:nbn:de:1111-2016030249811
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
2025-08-15T07:36:46+0200
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Riedel, Amy
- Choe, Lan
- Inciardi, John
- Yuen, Courtney
- Martin, Thomas
- Guglielmo, B Joseph
- SpringerLink (Online service)
Ähnliche Objekte (12)
Antifungal Prophylaxis in the Era of Targeted Chemotherapy for Acute Myelogenous Leukemia
Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis
Effectiveness and Safety of Filgrastim (Neupogen™) versus Filgrastim-aafi (Nivestim™) in Primary Prophylaxis of Chemotherapy-Induced Febrile Neutropenia: An Observational Cohort Study
Risk of chemotherapy-induced febrile neutropenia with early discontinuation of pegfilgrastim prophylaxis in US clinical practice
Results of a prospective dose intensity and neutropenia prophylaxis evaluation programme (DIEPP) in cancer patients at risk of febrile neutropenia due to myelosuppressive chemotherapy
Risk of chemotherapy-induced febrile neutropenia in cancer patients receiving pegfilgrastim prophylaxis: does timing of administration matter?
NADIR: A Non-Interventional Study on the Prophylaxis of Chemotherapy-Induced Neutropenia Using Lipegfilgrastim - First Interim Analysis
Zarzio®, biosimilar of filgrastim, in prophylaxis of chemotherapy-induced neutropenia in routine practice: a French prospective multicentric study
Pegfilgrastim for primary prophylaxis of febrile neutropenia in multiple myeloma
Chemotherapy and febrile neutropenia - diagnostic and therapeutic management
Fluconazole for empiric antifungal therapy in cancer patients with fever and neutropenia
Optimization of Antifungal Prophylaxis in Haematological High-Risk Patients
Antifungal Prophylaxis in the Era of Targeted Chemotherapy for Acute Myelogenous Leukemia
Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis
Effectiveness and Safety of Filgrastim (Neupogen™) versus Filgrastim-aafi (Nivestim™) in Primary Prophylaxis of Chemotherapy-Induced Febrile Neutropenia: An Observational Cohort Study
Risk of chemotherapy-induced febrile neutropenia with early discontinuation of pegfilgrastim prophylaxis in US clinical practice
Results of a prospective dose intensity and neutropenia prophylaxis evaluation programme (DIEPP) in cancer patients at risk of febrile neutropenia due to myelosuppressive chemotherapy
Risk of chemotherapy-induced febrile neutropenia in cancer patients receiving pegfilgrastim prophylaxis: does timing of administration matter?
NADIR: A Non-Interventional Study on the Prophylaxis of Chemotherapy-Induced Neutropenia Using Lipegfilgrastim - First Interim Analysis
Zarzio®, biosimilar of filgrastim, in prophylaxis of chemotherapy-induced neutropenia in routine practice: a French prospective multicentric study
Pegfilgrastim for primary prophylaxis of febrile neutropenia in multiple myeloma
Chemotherapy and febrile neutropenia - diagnostic and therapeutic management
Fluconazole for empiric antifungal therapy in cancer patients with fever and neutropenia
Optimization of Antifungal Prophylaxis in Haematological High-Risk Patients
Antifungal Prophylaxis in the Era of Targeted Chemotherapy for Acute Myelogenous Leukemia
Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis
Effectiveness and Safety of Filgrastim (Neupogen™) versus Filgrastim-aafi (Nivestim™) in Primary Prophylaxis of Chemotherapy-Induced Febrile Neutropenia: An Observational Cohort Study
Risk of chemotherapy-induced febrile neutropenia with early discontinuation of pegfilgrastim prophylaxis in US clinical practice
Results of a prospective dose intensity and neutropenia prophylaxis evaluation programme (DIEPP) in cancer patients at risk of febrile neutropenia due to myelosuppressive chemotherapy
Risk of chemotherapy-induced febrile neutropenia in cancer patients receiving pegfilgrastim prophylaxis: does timing of administration matter?
NADIR: A Non-Interventional Study on the Prophylaxis of Chemotherapy-Induced Neutropenia Using Lipegfilgrastim - First Interim Analysis
Zarzio®, biosimilar of filgrastim, in prophylaxis of chemotherapy-induced neutropenia in routine practice: a French prospective multicentric study
Pegfilgrastim for primary prophylaxis of febrile neutropenia in multiple myeloma
Chemotherapy and febrile neutropenia - diagnostic and therapeutic management
Fluconazole for empiric antifungal therapy in cancer patients with fever and neutropenia